LOG IN Provider Services Our tests help to identify the genomic alterations driving a patient's cancer and match them with relevant targeted therapies, immunotherapies, and clinical trial options. We also provide decision support services, clinical trial matching, and technology solutions to help support the genomic testing process. Partnering with Providers Foundation Medicine’s proven portfolio of tests and services offers the quality and commitment you need to help inform treatment strategies for your advanced cancer patients. Discover in-depth genomic insights and a breadth of offerings to help you integrate comprehensive genomic profiling into your practice. Comprehensive Genomic Profiling Tests Discover tissue- and blood-based FDA-approved comprehensive genomic profiling testing for all solid tumors with FoundationOne®CDx and FoundationOne®Liquid CDx. In addition, FoundationOne®Heme is a laboratory developed test for hematologic malignancies, sarcomas, or solid tumors where fusion detection is desired. LEARN MORE ABOUT OUR TESTS Online Ordering & Report Integrations Foundation Medicine offers online ordering, digital reporting, and EMR and API integrations to help integrate comprehensive genomic profiling into your workflow. LEARN MORE ABOUT ONLINE ORDERING AND REPORT INTEGRATIONS Clinical Research & Trial Matching Leverage our molecular information through our clinical research and trial matching services to help inform treatment decisions for your patients. LEARN MORE ABOUT CLINICAL RESEARCH AND TRIAL MATCHING Decision Support & Provider Education From interpretation of results on each report to expert consultations and ongoing education, we can help you make the most of comprehensive genomic profiling (CGP) in your practice. LEARN MORE ABOUT DECISION SUPPORT AND PROVIDER EDUCATION Foundation Facts & Figures Foundation Medicine has the most experience with comprehensive genomic profiling in the industry.* 500k+ PATIENT SAMPLES PROFILED 500+ PEER-REVIEWED PUBLICATIONS Latest Updates FoundationOne®Liquid CDx FoundationOne®Liquid CDx has been approved by the FDA as the only blood-based CGP companion diagnostic (CDx) for Tabrecta® (capmatinib). Our FDA-approved portfolio of both CGP tissue- and blood-based tests are now approved as the only CDx for Tabrecta® (capmatinib) in identifying advanced non-small cell lung cancer (NSCLC) patients having mutations that lead to METex14 skipping mutations and offers the highest number of CDx indications in NSCLC. LEARN MORE ABOUT FOUNDATIONONE LIQUID CDX FoundationOne®CDx Our FoundationOne CDx tissue-based test has been approved as the only FDA-approved companion diagnostic to detect NTRK1/2/3 fusions for Vitrakvi® (larotrectinib). LEARN MORE ABOUT FOUNDATIONONE CDX ADDITIONAL NOTES * As defined by the number of cancer patients tested by Foundation Medicine in a clinical setting with comprehensive genomic profiling and the amount of evidence published by Foundation Medicine in a research setting about comprehensive genomic profiling. Important Safety Information SELECT FoundationOne CDx FoundationOne Liquid CDx FoundationOne CDx FoundationOne CDx FoundationOne®CDx is a qualitative next-generation sequencing based in vitro diagnostic test for advanced cancer patients with solid tumors and is for prescription use only. The test analyzes 324 genes as well as genomic signatures including microsatellite instability (MSI) and tumor mutational burden (TMB) and is a companion diagnostic to identify patients who may benefit from treatment with specific therapies in accordance with the approved therapeutic product labeling. Additional genomic findings may be reported and are not prescriptive or conclusive for labeled use of any specific therapeutic product. Use of the test does not guarantee a patient will be matched to a treatment. A negative result does not rule out the presence of an alteration. Some patients may require a biopsy. For the complete label, including companion diagnostic indications and important risk information, please visit www.F1CDxLabel.com. PRODUCTS & SERVICES Our Tests Provider Services Biopharma Partner Services NEWS & EVENTS Press Releases Blog Events ABOUT US Our Story Leadership Team Careers CONTACT US LOGIN ORDER A TEST © 2021 FOUNDATION MEDICINE, INC. Legal & Privacy California Compliance Notice of Privacy Practices Licenses Update Cookie Preferences